Since the discovery that the receptor is overexpressed in a variety of solid tumors, such as pancreatic, breast and lung cancer, many studies have focused on methods for targeting CD44 in an attempt to improve drug delivery and discrimination between healthy and malignant tissue, while reducing residual toxicity [44]. This evidence concerns the gene CD44 and lung cancer.